What is TBPH's P/E ratio?

Theravance Biopharma Inc (TBPH) currently trades at a P/E ratio of 7.32.

Theravance Biopharma Inc reports a Return on Equity (ROE) of 39.42%.

What is TBPH's dividend yield?

Theravance Biopharma Inc offers a dividend yield of 0.00%.

What is TBPH's Quality Score?

Our AI rates TBPH's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TBPH?

Our AI Timing Score for TBPH is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TBPH belong to?

Theravance Biopharma Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Theravance Biopharma Inc (TBPH) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

TBPH AI Analysis Summary

Our AI summary for TBPH: Theravance Biopharma Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 7.32, ROE of 39.42%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TBPH

Theravance Biopharma Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 16.88

0.01 (0.06%) Day Change

Watchlist Portfolio Compare Chart

7.32

P/E

0.04

D/E

39.4%

ROE

24.3%

ROA

0.00%

Div Yield

-0.06

PEG

THERAVANCE BIOPHARMA INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 16.88 Price 0.01 (0.06%) Day Change	NEWS SCORE: N/A

TBPH, the overall quality is good ( Quality = 77) and the timing to buy is ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Acceleration of ROE growth rate is below our criteria.
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...

Quality Factors

60%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.13 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	111
Magic Formula Rank by ROE	111
Magic Formula Rank by ROIC	104
Price	16.88
PBV / Sector	3.01 / 44,022.72
Earning Per Share	2.21

PE / Sector	7.32 / 19.17 GREAT
PEG or PE/Growth / Sector	-0.06 / 1.24
Average 1M Daily Value	9.36 M
Average 1W Daily Value	6.83 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

47%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	104.34 / 98.24 GREAT
NPM Average (%) / Sector	343.53 / -1,697.63 GREAT
NPM Change Average (%) / Sector	-80.26 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	24.25 / 185,260.96 GOOD
ROA Average (%) / Sector	31.85 / 36,684.70 GREAT
ROA Change Average (%) / Sector	-81.38 / 422,221.66
ROE (%) / Sector	39.42 / 243,762.23 GREAT
ROE Average (%) / Sector	42.89 / 48,758.47 GREAT
ROE Change Average (%) / Sector	-72.42 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:56
Symbol	TBPH
Name	THERAVANCE BIOPHARMA INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	51.83 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	874.34 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080

Phone: 650 808 6000

Website: https://www.theravance.com

Employees: 90

Sector: Healthcare >> Biotechnology

Description: Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.